Olmesartan + amlodipine + rosuvastatin + ezetimibe is under clinical development by Daewoong Pharmaceutical and currently in Phase I for Hypercholesterolemia. According to GlobalData, Phase I drugs for Hypercholesterolemia have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Olmesartan + amlodipine + rosuvastatin + ezetimibe’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Olmesartan + amlodipine + rosuvastatin + ezetimibe overview
DWJ-1451 is a four drug combination of olmesartan, amlodipine, rosuvastatin, ezetimibe. It is under development for the treatment of essential hypertension (idiopathic (essential) hypertension), primary hypercholesterolemia. It is administered as tablet through oral route.
It was under development for the treatment of hypertension, dyslipidemia.
Daewoong Pharmaceutical overview
Daewoong Pharmaceutical, a subsidiary of Daewoong Co Ltd, is a manufacturer and distributor of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, healthcare products and APIs. The company produces products in the form of tablets, capsules, ointments, injections, liquids, and sprays. It offers products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system remedies. It also carries out the development and commercialization of products through in-licensing, co-marketing and co-promotion. The company operates in Japan, the US, Canada, Switzerland, Germany, Indonesia, China, Vietnam, Israel, Thailand, and India in Asia. Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
For a complete picture of Olmesartan + amlodipine + rosuvastatin + ezetimibe’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
